444 Basiliximab Simulect

  • Basiliximab (Simulect)

    Simulect is a monoclonal antibody that functions as an immunosuppressive agent. 

    It is indicated for the prophylaxis of acute rejection following renal transplantation. 

    It is directed against the interluekin-2 receptor alpha-chain (CD25 antigen), which is expressed on the surface of the T-lymphocytes in response to antigenic challenge. 

    Basiliximab specifically binds to the CD25 antigen on activated t-cells from starting the rejection process


    20mg vial of freeze dried powder for reconstitution with water for injections.  In most cases the drug will be reconstituted (20mg in 5ml water) in Pharmacy within 24 hours of use


    2 doses according to weight (age) up to a maximum of 2 doses of 20mg - 10mg <40kg 20mg >40kg

    • the first dose is given 2 hours prior to transplant surgery and 
    • the second dose is given 4 days post-transplantation

    Blood levels

    Complete and consistent blocking of the interluekin-2 receptor is maintained as long as serum basiliximab levels exceed 0.2 micrograms/ml


    In controlled trials adverse events experienced with patients receiving basiliximab were indistinguishable from those treated with placebo

    A number of cases of a syndrome of fever, rash, pulmonary oedema and renal impairment occurring within 24 hours of basiliximab have been described.  In such cases the second dose of basiliximab (if not given) should not be given.